TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $6.04 million.

Recent Highlights

• Net revenue of $7.6 million in the fourth quarter of 2020, representing 26% growth compared to the fourth quarter of 2019
• Expanded the National OCS Program to include 5 new U.S. regions
• Initiated the OCS Heart DCD CAP program in 25 U.S. heart transplant centers
• Completed enrollment of the OCS Liver PROTECT CAP first tranche of 74 patients
• Appointed Merilee Raines to Board of Directors
• Announced scheduling of OCS Heart FDA Advisory Panel Committee Meeting on April 6, 2021

"Fourth quarter sales exceeded expectations and were driven primarily by the recovery of U.S. OCS Lung procedure volumes as well as progress with the OCS DCD Heart and the OCS Liver CAP clinical programs," said Waleed Hassanein, MD, President and Chief Executive Officer. "We are now focused on leveraging the progress made with our National OCS Program in 2020 and advancing our FDA initiatives in the upcoming months to accelerate our growth through 2021 and beyond."

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.